Hit enter to search or ESC to close

News

Dr David Stamler appointed CEO

The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately. Dr Stamler joined the Company in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development.  Mr Geoffrey Kempler, who founded ...

Alterity and UniQuest to reverse bacterial resistance to antibiotics

New commercial opportunity for PBT2 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimicrobial resistance in superbugs. Under the licence, Alterity has secured the worldwide exclusive ...

Alterity presents at Finance News Network investor event

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO and Chairman Mr Geoffrey Kempler will present to investors at the Finance News Network event today at 12.55pm. The event is partnered with stockbroking firm Shaw and Partners and is expected to be attended by trustees of self- managed superannuation funds, high net-worth investors, ...

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).  The new patent is the product of in-house discovery research and is central to Alterity’s next generation drug development portfolio focussed on neurodegenerative diseases. ...

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Alterity Therapeutics today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States. BioMUSE is a natural history study that aims to track the progression of patients with MSA, a Parkinsonian disorder without approved therapy.  The study is being conducted in collaboration with Vanderbilt University Medical ...

Alterity completes Placement Tranche 1 raising $10M

$25M Second Tranche to complete following shareholder approval Alterity completes Tranche 1 of Placement raising $10M Tranche 2 completes on 18th November pending shareholder approval raising an additional $25M Alterity Therapeutics today lodged its Appendix 2A confirming the allocation and quotation of 271,251,007 shares as consideration under Tranche One of a $35M Placement to institutional ...

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Successfully obtained binding commitments for A$35M via institutional placement to be settled in 2 tranches Tranche 1: $10M raised under Alterity’s current placement capacity Tranche 2: $25M subject to shareholder approval Attached 1.1 option under Tranche 2 The capital raising was cornerstone by top tier institutional investors in Australia and North America and supported by ...

Receive news from Alterity Therapeutics